Endocrine Therapy Combined with Targeted Therapy in Hormone Receptor-Positive Metastatic Breast Cancer

0
0
0

Endocrine Therapy Combined with Targeted Therapy in Hormone Receptor-Positive Metastatic Breast Cancer

Hormone receptor (HR)-positive metastatic breast cancer (MBC), characterized by estrogen receptor (ER) and/or progesterone receptor (PR) expression, represents approximately 70% of all breast cancer cases. Endocrine therapy remains the cornerstone of treatment for this subtype. However, resistance to endocrine agents frequently develops, necessitating innovative strategies to overcome therapeutic limitations. The integration of targeted therapies with endocrine treatments has emerged as a transformative approach, ushering in a new era of precision medicine for HR-positive MBC. This review examines the evolution of endocrine therapy, molecular mechanisms of resistance, and breakthroughs in combining endocrine agents with targeted drugs.

Evolution of Endocrine Therapy in Metastatic Breast Cancer

The transition from the “aromatase inhibitor (AI) era” to the “post-AI era” marked a paradigm shift in endocrine therapy. Fulvestrant, a selective estrogen receptor degrader (SERD), gained prominence due to its efficacy in patients progressing on prior endocrine treatments. Key clinical trials solidified its role:

  • CONFIRM Trial: Demonstrated superior progression-free survival (PFS) with fulvestrant 500 mg vs. 250 mg (median PFS: 6.5 vs. 5.5 months; HR = 0.80, P = 0.006).
  • FALCON Trial: Compared fulvestrant 500 mg to anastrozole in first-line therapy, showing improved median PFS (16.6 vs. 13.8 months; HR = 0.79, P = 0.048).

For premenopausal patients, ovarian suppression combined with endocrine therapy is standard. The PROOF Trial (ongoing) evaluates fulvestrant + goserelin vs. anastrozole + goserelin in Chinese premenopausal women, aiming to establish optimal first-line regimens.

Molecular Mechanisms of Endocrine Resistance

Resistance to endocrine therapy arises from estrogen-independent ER activation via multiple pathways:

  1. Cyclin D-CDK4/6-Rb Pathway: Cross-talk between cell cycle regulators and ER signaling drives proliferation.
  2. Epigenetic Dysregulation: Histone deacetylases (HDACs) alter chromatin structure, suppressing tumor suppressor genes.
  3. ESR1 Mutations: Acquired mutations in the ER gene confer ligand-independent activation.
  4. Growth Factor Receptor Aberrations: Amplification/mutation of tyrosine kinases (e.g., FGFR, IGF-1R) activates alternative pathways.
  5. PI3K-AKT-mTOR Pathway: Hyperactivation promotes cell survival and therapy resistance.

These mechanisms underpin the development of targeted agents designed to restore endocrine sensitivity.

CDK4/6 Inhibitors: Revolutionizing First-Line Therapy

CDK4/6 inhibitors, including palbociclib, ribociclib, and abemaciclib, synergize with endocrine therapy by blocking cell cycle progression. Clinical trials demonstrate unprecedented efficacy:

First-Line Combinations with AIs

  • PALOMA-2: Palbociclib + letrozole vs. letrozole alone (median PFS: 27.6 vs. 14.5 months; HR = 0.56, P < 0.001).
  • MONALEESA-7: Ribociclib + NSAI + goserelin in premenopausal women (median PFS: 23.8 vs. 13.0 months; HR = 0.55, P < 0.0001). OS data revealed a 29% reduction in death risk (HR = 0.71, P = 0.00973).
  • MONARCH-3: Abemaciclib + NSAI (median PFS: 28.1 vs. 14.7 months; HR = 0.54, P = 0.000021).

Later-Line Combinations with Fulvestrant

  • PALOMA-3: Palbociclib + fulvestrant in AI-resistant patients (median PFS: 9.5 vs. 4.6 months; HR = 0.50, P < 0.0001). OS trended favorably (34.9 vs. 28.0 months; HR = 0.81).
  • MONARCH-2: Abemaciclib + fulvestrant (median PFS: 16.4 vs. 9.3 months; HR = 0.55, P < 0.001).

HDAC Inhibitors: Epigenetic Modulation

Tucidinostat, a Chinese-developed HDAC inhibitor, reverses epigenetic silencing of ER-responsive genes. The ACE Trial validated its efficacy:

  • Tucidinostat + exemestane vs. placebo + exemestane in AI-resistant patients (median PFS: 7.4 vs. 3.8 months; HR = 0.75, P = 0.033). ORR and CBR were doubled (18.4% vs. 9.1%; 46.7% vs. 35.5%).

Targeting the PI3K-AKT-mTOR Axis

PI3K Inhibitors

  • SOLAR-1: Alpelisib (PI3Kα inhibitor) + fulvestrant in PIK3CA-mutant tumors (median PFS: 11.0 vs. 5.7 months; HR = 0.65, P < 0.001). This led to FDA approval for PIK3CA-mutant HR+/HER2− MBC.
  • SANDPIPER: Taselisib + fulvestrant showed modest PFS improvement (7.4 vs. 5.4 months; HR = 0.70) but significant toxicity.

AKT/mTOR Inhibitors

  • FAKTION: Capivasertib (AKT inhibitor) + fulvestrant (median PFS: 10.3 vs. 4.8 months; HR = 0.57, P = 0.0035).
  • BOLERO-2: Everolimus (mTOR inhibitor) + exemestane (median PFS: 7.8 vs. 3.2 months; HR = 0.45, P < 0.0001).

Anti-HER2 Combinations in HR+/HER2+ MBC

For HR+/HER2+ tumors, dual HER2 blockade + endocrine therapy improves outcomes:

  • TAnDEM: Trastuzumab + anastrozole vs. anastrozole (median PFS: 4.8 vs. 2.4 months; HR = 0.63, P = 0.0016).
  • MonarcHER: Abemaciclib + trastuzumab + fulvestrant vs. chemotherapy + trastuzumab (median PFS: 8.3 vs. 5.7 months; ORR: 32.9% vs. 13.9%).

Future Directions and Biomarker Exploration

Despite progress, challenges remain in optimizing sequencing and identifying predictive biomarkers. Current research focuses on:

  • ESR1 Mutation Status: Guides fulvestrant use in AI-resistant cases.
  • PIK3CA Mutations: Mandate alpelisib combination therapy.
  • p4EBP1 Expression: Predicts everolimus efficacy (SAFIRTOR Trial: PFS 9.3 vs. 5.8 months, P = 0.0221).

Conclusion

The integration of CDK4/6 inhibitors, HDAC inhibitors, and PI3K/AKT/mTOR pathway blockers with endocrine therapy has redefined HR-positive MBC management. Tailoring treatments based on molecular profiles and resistance mechanisms will further enhance precision. As the field advances, biomarker-driven strategies and novel combinations promise to extend survival and improve quality of life for patients.

doi.org/10.1097/CM9.0000000000000923

Was this helpful?

0 / 0